KellyNGodbyMD
Oncology • Birmingham, ALAssociate Professor, Medicine, University of Alabama School of Medicine
Overview of Dr. Godby
Dr. Kelly Godby is an oncologist in Birmingham, AL and is affiliated with multiple hospitals in the area, including University of Alabama Hospital and USA Health University Hospital. She received her medical degree from Mercer University School of Medicine and has been in practice 12 years. She is one of 65 doctors at University of Alabama Hospital and one of 38 doctors at USA Health University Hospital who specialize in Oncology. She has more than 30 publications and over 500 citings.
Office
2000 6th Ave S
Birmingham, AL 35233- Is this information wrong?
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011- University of Alabama Medical CenterResidency, Internal Medicine, 2005 - 2008
Mercer University School of MedicineClass of 2005
Certifications & Licensure
AL State Medical License 2007 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.Nadia M Anabtawi, Monica Sai Pasala, Alyssa A Grimshaw, Prakash Kharel, Thomas W Buford, Susan Bal, Kelly Godby, Ashmita Siwakoti, Smita Bhatia, Luciano J Costa, Grant...> ;Journal of Cachexia, Sarcopenia and Muscle. 2024 Apr 1
- Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations.Gayathri Ravi, Susan Bal, Laura Joiner, Smit Giri, Melissa Sentell, Tiffany Hill, Kelly N Godby, Luciano J Costa> ;British Journal of Haematology. 2024 Apr 1
- 4 citationsMinimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Costa, L., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T., Godby, K., Silbermann, R., Dhakal, B., Bal, S., Giri, S., D'Souza, A., Hall, A., Hardwick, P., Omel, ...> ;The Lancet. Haematology. 2023 Nov 1
- Join now to see all
Journal Articles
- Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific MortalityParameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology
Abstracts/Posters
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...Kelly N. Godby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hospital Affiliations
University of Alabama HospitalBirmingham, Alabama
USA Health University HospitalMobile, Alabama
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
